Quick Answer
TriSalus Life Sciences, Inc. reported Diluted EPS of $1.84 per share (loss) for fiscal year 2025.
TriSalus Life Sciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.84 | -40.5% |
| 2024 | -$1.31 | +80.6% |
| 2023 | -$6.77 | +95.8% |
| 2022 | -$161.55 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.96 | -700.0% | -255.6% |
| June 30, 2025 | -$0.27 | -28.6% | +30.8% |
| March 31, 2025 | -$0.39 | +35.0% | -225.0% |
| September 30, 2024 | -$0.12 | +14.3% | +42.9% |
| June 30, 2024 | -$0.21 | +99.4% | +65.0% |
| March 31, 2024 | -$0.60 | -5.3% | -328.6% |
| September 30, 2023 | -$0.14 | +99.5% | +99.6% |
| June 30, 2023 | -$35.84 | — | -6187.7% |
- TriSalus Life Sciences, Inc. showed a decrease of -40.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, TriSalus Life Sciences, Inc.’s diluted eps has grown by 98.9% (from $161.55 per share (loss) to $1.84 per share (loss)).
- The most recent figure is from TriSalus Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: